Cofactor Genomics is a biotechnology startup founded in 2015 with a mission to revolutionize diagnostics in the field of healthcare. With the slogan "The Leaders in RNA," the company leverages multidimensional biomarkers created with RNA and machine learning to develop diagnostics that can predict which patients will benefit from immunotherapies.
Unlike traditional tests that focus on isolated biomarkers or DNA mutations, Cofactor Genomics creates multidimensional biomarkers that offer greater predictive power, capturing the complex immune response at tumor sites. This approach provides clinicians with more insightful information, enabling them to make better-informed treatment decisions, ultimately improving patient outcomes.
The company is based in the United States and has recently received a $1.17M Venture Round investment from Mission and Market in 02 August 2023. With its innovative approach and focus on advancing precision medicine, Cofactor Genomics demonstrates potential for significant impact in the biotechnology and healthcare industries. Its emphasis on leveraging RNA and machine learning positions the company as a leader in the development of predictive diagnostics, making it an attractive prospect for investors seeking cutting-edge technologies with the potential to drive meaningful change in personalized medicine.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Venture Round | $1.17M | 1 | 02 Aug 2023 | |
Venture Round | $6.91M | - | 16 Dec 2021 | |
Series A | $18.00M | 10 | Wilson Sonsini Goodrich & Rosati, Stanford University +1 | 18 Sep 2017 |
Seed Round | $120.00K | 1 | 18 Aug 2015 | |
Seed Round | $2.63M | 10 | Paul Buchheit, Jude Gomila +3 | 31 Jul 2015 |
No recent news or press coverage available for Cofactor Genomics.